Nicox made good progress during the first quarter of 2012, which was marked by the Company’s first step towards building an international ophthalmology company and by Bausch + Lomb’s decision to progress BOL-303259-X into phase 3, which supports the potential of our R&D platform in ophthalmology, said Michele Garufi, Chairman and CEO of Nicox.

If we decide to exercise the option to acquire Altacor, Nicox would benefit from an experienced sales infrastructure in the UK with a range of marketed products and from ALT-005 and SOLO potential to drive future international growth. We are in advanced discussions with a number of parties to secure additional acquisition and inlicensing deals to build a diversified, late-stage ophthalmic portfolio with a clear route to commercialisation in the major markets.